Thursday: arms again with bilateral injection
Monitoring approach: Establish clear metrics (visual field, OCT, visual acuity), measure every 3-6 months, continue peptides if stable or improving, consider break if stable 12+ months on treatment, resume immediately if decline detected during break, accept ongoing use if clearly beneficial and well-tolerated
FAQs Common misconceptions and questions related to peptide therapy Is Peptide Therapy Safe
Clinical studies document sustained improvements over extended use
This article reports that discontinuation of semaglutide 2.4 mg is followed by weight regain, supporting the need for continued treatment to maintain weight loss
For subcutaneous injections, a standard insulin syringe is typically used